(MedPage Today) — NEW ORLEANS — Treatment with the PCSK9 inhibitor alirocumab (Praluent) safely lowered LDL cholesterol versus placebo in transplant patients already on rosuvastatin, but did not reduce the development of cardiac allograft vasculopathy…
Source link : https://www.medpagetoday.com/meetingcoverage/aha/118534
Author :
Publish date : 2025-11-14 19:55:00
Copyright for syndicated content belongs to the linked Source.
